Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesZelira Therapeutics Ltd

Zelira Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.5 AUD 0.00(0%)
Last update at 2026-11-10T23:00:00Z
Market Cap
6.57M

Momentum Score

…

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.50
Low
0.50
High
52 Week Price Range
0.33
Low
1.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Zelira Therapeutics Ltd is an Australian biotechnology company developing and commercializing cannabinoid-based medicines and wellness products for neurological and chronic conditions. Long-term growth could be supported by clinical trial progress, distribution agreements and wider regulatory acceptance of medical cannabis in markets. Investors may find the company attractive because it appears positioned to convert proprietary formulations and clinical data into recurring revenue if access is secured.
Material risks include clinical or regulatory failure, competitive and commercial execution challenges, limited financing and dependence on partner agreements and changing legal or reimbursement regimes.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.50
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.80M
Debt / Equity
-0.85
ROE
-266.82%
Net Debt
1.98M
ROCE
100.72%
Diluted EPS TTM
-0.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -3.85M -36.74M -6.27M -12.41M -8.55M
Minority interest 0.22M 0.17M 0.70M 0.47M -
Net income -3.63M -36.57M -5.57M -11.95M -8.55M
Selling general administrative 1.65M 1.34M 3.06M 6.08M 4.49M
Selling and marketing expenses 0.01M 0.03M 0.07M 0.72M 0.51M
Gross profit -0.80M 0.01M -0.06M 0.60M 0.44M
Reconciled depreciation 0.27M 0.48M 0.55M 0.59M 0.47M
Ebit -4.32M -36.92M -5.93M -12.36M -8.51M
Ebitda -4.17M -36.44M -5.38M -11.77M -8.03M
Depreciation and amortization 0.15M 0.48M 0.55M 0.59M 0.47M
Operating income -3.95M -5.94M -7.16M -13.21M -9.38M
Other operating expenses 3.95M 6.27M 6.49M 13.91M 9.17M
Interest expense 0.41M 0.74M 0.08M 0.05M 0.04M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income - 0.00M 0.08M 0.01M 0.00M
Net interest income -0.41M -0.74M -0.08M -0.04M -0.04M
Income tax expense -1.15M -0.92M 0.72M 0.86M 1.30M
Total revenue 0.00M 0.09M 0.30M 1.54M 0.66M
Total operating expenses 3.15M 5.95M 7.20M 14.25M 10.20M
Cost of revenue 0.80M 0.08M 0.36M 0.94M 0.23M
Total other income expense net 0.10M -30.80M 1.07M 1.28M 1.25M
Net income from continuing ops -3.85M -36.74M -6.27M -12.41M -8.55M
Net income applicable to common shares -3.63M -36.57M -5.57M -11.95M -8.55M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 1.30M 5.18M 33.89M 37.70M 39.37M
Intangible assets 0.52M - 0.81M 0.97M 1.12M
Other current assets - 0.11M 0.11M 0.27M 0.21M
Total liab 5.59M 9.36M 2.18M 2.01M 1.54M
Total stockholder equity -4.46M -4.51M 31.80M 35.20M 37.83M
Other current liab - - 0.14M 0.12M 0.09M
Common stock - 45.52M 45.52M 43.75M 36.65M
Capital stock 45.52M - 45.52M 43.75M 36.65M
Retained earnings -84.96M -81.34M -44.77M -39.19M -27.25M
Good will - - 30.75M 30.75M 30.75M
Other assets - - 0.04M 0.06M 0.10M
Cash 0.01M 0.59M 0.15M 2.75M 4.97M
Total current liabilities 5.59M 7.09M 1.88M 1.63M 1.08M
Current deferred revenue - - -0.14M -0.12M -0.09M
Net debt 1.98M 3.25M 0.29M -2.25M -4.42M
Short term debt - 3.69M 0.14M 0.12M 0.09M
Short long term debt 1.99M - - - -
Short long term debt total - 3.84M 0.44M 0.50M 0.55M
Other stockholder equity - - -0.57M 30.65M 28.43M
Property plant equipment - - 0.52M 0.85M 1.24M
Total current assets 0.61M 4.26M 1.77M 5.08M 6.09M
Long term investments 0.04M - 0.04M 0.06M 0.17M
Net tangible assets - - 0.24M 3.49M 5.96M
Short term investments - - - - -0.10M
Net receivables 0.00M 2.31M -0.00M 0.26M 0.06M
Inventory 0.48M 1.25M 1.53M 1.96M 0.87M
Accounts payable 3.45M 3.41M 1.74M 1.51M 0.98M
Accumulated other comprehensive income - 31.31M 31.05M 30.65M 28.43M
Non currrent assets other - 0.65M -32.08M -32.56M -33.18M
Non current assets total 0.69M 0.92M 32.12M 32.63M 33.28M
Capital lease obligations 0.15M - 0.44M 0.50M 0.55M
Long term debt total - - 0.30M 0.38M 0.46M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 1.15M 0.92M 2.83M -0.21M 1.38M
Change to liabilities - - 0.23M 0.53M 0.43M
Total cashflows from investing activities 1.15M 0.92M 2.83M -0.21M 1.38M
Net borrowings 3.19M 3.92M - - -
Total cash from financing activities 3.19M 3.92M 1.77M 7.10M 10.53M
Net income -3.63M -36.57M -5.57M -11.95M -8.55M
Change in cash -0.58M 0.60M -2.60M -2.22M 3.27M
Begin period cash flow 0.59M -0.02M 2.75M 4.97M 1.70M
End period cash flow 0.01M 0.59M 0.15M 2.75M 4.97M
Total cash from operating activities -4.91M -4.39M -7.25M -9.43M -8.62M
Issuance of capital stock - - 1.77M 7.10M 10.62M
Depreciation 0.27M 0.48M 0.55M 0.59M 0.47M
Other cashflows from investing activities 1.15M 0.92M 2.83M -0.21M 1.38M
Change to inventory 0.77M 0.28M 0.36M -1.09M -0.87M
Change to account receivables 0.18M -0.21M 0.28M -0.12M -0.12M
Sale purchase of stock -0.00M - 1.77M 7.10M -0.09M
Other cashflows from financing activities 1.09M 0.92M 2.83M -0.21M 1.38M
Change to netincome - - -3.08M 2.62M 0.02M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.95M 1.73M 0.63M -1.21M -0.98M
Stock based compensation -1.19M 0.04M 0.40M 2.69M 1.30M
Other non cash items -1.31M 30.41M -2.22M 1.93M -0.54M
Free cash flow -4.91M -4.39M -7.25M -9.43M -8.62M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ZLD
Zelira Therapeutics Ltd		 -
-%		 0.50 - 5.78 10020.70 0.33 12323.71 -1.09
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Zelira Therapeutics Ltd

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.

101 St Georges Terrace, Perth, WA, Australia, 6000

61 8 6558 0886

https://zeliratx.com

Name Title Year Born
Mr. Osagie O. Imasogie Esq. Founder & Chairman 1962
Dr. Oludare Odumosu MD, Global CEO & Director NA
Mr. Timothy Ryan Slate Non-Exec. Director & Company Sec. NA
Mr. Rahul Ganesan VP of Fin. & Accounting NA
Mr. Greg Blake VP of Global and Head of Commercial & Partnering NA
Dr. Patty Washer Clinical Trial Consultant NA
Mr. Greg Blake Executive Director NA
Mr. Timothy Ryan Slate Company Secretary & Non-Executive Director NA
Mr. Rahul Ganesan Vice President of Finance & Accounting NA
Mr. Greg Blake Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…